Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07006727 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
A Phase 1 study of Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
- 5
- Study locations
NCT07006727: Recruiting Phase 1 study of Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung, sponsored by Novartis Pharmaceuticals.
NCT07006727 is a Phase 1 study of Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 116 participants, below the 255-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target (55% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07006727, a Phase 1 study of Small Cell Lung Carcinoma and Large Cell Neuroendocrine Carcinoma of the Lung, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
Primary Outcome
A dose limiting toxicity (DLT) is defined as any adverse event or abnormal laboratory value of CTCAE 5.0 grade 3 or higher that occurs within the DLT evaluation period and that is not primarily related to disease, disease progression, intercurrent illness, or concomitant medications with a few exceptions defined in the study protocol. Other significant toxicities may be considered to be DLTs, even if not Grade 3 or higher.
Conditions Studied
Interventions
- DRUG 225Ac-ETN029
- DRUG 111In-ETN029
Study Locations (5)
Iowa
- University Of Iowa - Iowa City
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Corewell Health William Beaum Hosp - Royal Oak
Quebec
- Novartis Investigative Site - Montreal
Korea
- Novartis Investigative Site - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-10-16 |
| Est. Completion | 2031-06-17 |
| Phase | Phase 1 |
What NCT07006727 shows while recruiting
NCT07006727 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 255-participant average among 18 other Small Cell Lung Carcinoma trials with a reported enrollment target (55% lower).
The record links to 4 conditions, with Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which 225Ac-ETN029 is the first listed.
NCT07006727 lists 5 locations in 5 states (Iowa, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT07006727 about?
NCT07006727 is a clinical study titled "Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[225Ac\]Ac-ETN029 and the safety and imaging properties of \[111In\]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers.
What is the current status of trial NCT07006727?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2025-10-16. Estimated completion is 2031-06-17.
What conditions does trial NCT07006727 study?
This clinical trial studies the following conditions: Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma.
What interventions are being tested in trial NCT07006727?
The interventions under investigation include: 225Ac-ETN029 (DRUG), 111In-ETN029 (DRUG).
Who is sponsoring clinical trial NCT07006727?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07006727 being conducted?
This trial has 5 study locations across Iowa, Massachusetts, Michigan, Quebec, Korea. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07006727's enrollment target sits among peer trials
116 9th of 18 higher than 10 of 18 other Small Cell Lung Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small Cell Lung Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
RECRUITING · Phase 1
-
Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
RECRUITING · Phase 1
-
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
RECRUITING · Phase 1
-
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI